CRP and congenital rubella syndrome: Siltuximab, an anti-interleukin-6 monoclonal antibody, was administered instead of corticosteroids when CRP exceeded 40 mg/L with a rapid 24-hour increase, based on predictive mathematical modeling, to preempt cytokine release syndrome (CRS).